奧昔布寧

奧昔布寧
臨床資料
商品名（英語：Drug nomenclature）	Ditropan
AHFS/Drugs.com	Monograph
MedlinePlus	a682141
核准狀況	歐 EMA: yes;
懷孕分級	澳: B1 ; ;
給藥途徑	口服給藥、transdermal（英語：transdermal） gel、transdermal patch（英語：transdermal patch）
ATC碼	G04BD04 (WHO) ;
法律規範狀態
法律規範	澳：限醫生處方（S4）; 加：處方藥（℞-only）; 英：處方藥（℞-only） (POM); 美：處方藥（℞-only） and OTC;
藥物動力學數據
血漿蛋白結合率	91–93%
生物半衰期	12.4–13.2 hours
識別資訊
	IUPAC命名法 4-Diethylaminobut-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylethanoate; ;
CAS號	5633-20-5
PubChem CID	4634;
IUPHAR/BPS	359;
DrugBank	DB01062 ;
ChemSpider	4473 ;
UNII	K9P6MC7092;
KEGG	D00465 ;
ChEBI	CHEBI:7856 ;
ChEMBL	ChEMBL1231 ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID0023406 ;
ECHA InfoCard	100.158.590
化學資訊
化學式	C22H31NO3
摩爾質量	357.486 g/mol
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES O=C(OCC#CCN(CC)CC)C(O)(c1ccccc1)C2CCCCC2;
	InChI InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3 ; Key:XIQVNETUBQGFHX-UHFFFAOYSA-N ;

奧昔布寧（Oxybutynin），商品名Ditropan、Lyrinel XL、Lenditro (ZA)、Driptane (RU)、Uripan (Middle East)^[1]，為一種抗膽鹼劑，可以緩解膀胱排尿困難，包含頻尿及尿失禁等症狀，可以降低膀胱肌肉痙攣^[2]。本品也可用於幫助緩解與腎結石相關的症狀。

本品可競爭性拮抗M₁（英語：Muscarinic acetylcholine receptor M1）、M₂（英語：Muscarinic acetylcholine receptor M2），及M₃（英語：Muscarinic acetylcholine receptor M3）等蕈毒鹼型乙醯膽鹼受體。

本品可能也可用於治療多汗症^[3]^[4]^[5]。

立體化學

奧昔布寧含有一個立體中心，由兩種對映體組成。這是外消旋體，即1：（R）的1:1混合物 - 和（S）形式:^[6]^[7]

奧昔布寧的對映體
CAS-Nummer: 119618-21-2	CAS-Nummer: 119618-22-3

參考文獻

^ Uripan Tablets. Adwia Pharmaceuticals. [22 November 2015]. （原始內容存檔於2020-10-26）.
^ Chapple CR. "Muscarinic receptor antagonists in the treatment of overactive bladder". Urology (55)5, Supp. 1:33-46, 2000.
^ Tupker RA, Harmsze AM, Deneer VH. Oxybutynin therapy for generalized hyperhidrosis.. Arch Dermatol. 2006, 142 (8): 1065–6. PMID 16924061. doi:10.1001/archderm.142.8.1065.
^ Mijnhout GS, Kloosterman H, Simsek S, Strack van Schijndel RJ, Netelenbos JC. Oxybutynin: dry days for patients with hyperhidrosis.. Neth J Med. 2006, 64 (9): 326–8. PMID 17057269.
^ Schollhammer M, Misery L. Treatment of hyperhidrosis with oxybutynin.. Arch Dermatol. 2007, 143 (4): 544–5. PMID 17438194. doi:10.1001/archderm.143.4.544.
^ Kachur JF, et al. R and S enantiomers of oxybutynin: pharmacological effects in guinea pig bladder and intestine, Journal of Pharmacology and Experimental Therapeutics, 247, S. 867–872, 1988; PMID 2849672.
^ Noronha-Blob L, Kachur JF. Enantiomers of oxybutynin: in vitro pharmacological characterization at M₁, M₂ and M₃ muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs, Journal of Pharmacology and Experimental Therapeutics, 256, S. 562–567, 1991; PMID 1993995.

外部連結

Template:Urologicals

Template:Muscarinic acetylcholine receptor modulators

[1] Uripan Tablets. Adwia Pharmaceuticals. [22 November 2015]. （原始內容存檔於2020-10-26）.

[2] Chapple CR. "Muscarinic receptor antagonists in the treatment of overactive bladder". Urology (55)5, Supp. 1:33-46, 2000.

[3] Tupker RA, Harmsze AM, Deneer VH. Oxybutynin therapy for generalized hyperhidrosis.. Arch Dermatol. 2006, 142 (8): 1065–6. PMID 16924061. doi:10.1001/archderm.142.8.1065.

[4] Mijnhout GS, Kloosterman H, Simsek S, Strack van Schijndel RJ, Netelenbos JC. Oxybutynin: dry days for patients with hyperhidrosis.. Neth J Med. 2006, 64 (9): 326–8. PMID 17057269.

[5] Schollhammer M, Misery L. Treatment of hyperhidrosis with oxybutynin.. Arch Dermatol. 2007, 143 (4): 544–5. PMID 17438194. doi:10.1001/archderm.143.4.544.

[6] Kachur JF, et al. R and S enantiomers of oxybutynin: pharmacological effects in guinea pig bladder and intestine, Journal of Pharmacology and Experimental Therapeutics, 247, S. 867–872, 1988; PMID 2849672.

[7] Noronha-Blob L, Kachur JF. Enantiomers of oxybutynin: in vitro pharmacological characterization at M₁, M₂ and M₃ muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs, Journal of Pharmacology and Experimental Therapeutics, 256, S. 562–567, 1991; PMID 1993995.

[1]

[2]

[3]

[4]

[5]

[6]

[7]